Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect

Seo, Youn Gee, Kim, Dae Hwan, Ramasamy, Thiruganesh, Kim, Jeong Hwan, Marasini, Nirmal, Oh, Yu-Kyoung, Kim, Dong-Wuk, Kim, Jin Ki, Yong, Chul Soon, Kim, Jong Oh and Choi, Han-Gon (2013) Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. International Journal of Pharmaceutics, 452 1-2: 412-420. doi:10.1016/j.ijpharm.2013.05.034


Author Seo, Youn Gee
Kim, Dae Hwan
Ramasamy, Thiruganesh
Kim, Jeong Hwan
Marasini, Nirmal
Oh, Yu-Kyoung
Kim, Dong-Wuk
Kim, Jin Ki
Yong, Chul Soon
Kim, Jong Oh
Choi, Han-Gon
Title Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect
Journal name International Journal of Pharmaceutics   Check publisher's open access policy
ISSN 0378-5173
1873-3476
Publication date 2013-08-16
Sub-type Article (original research)
DOI 10.1016/j.ijpharm.2013.05.034
Open Access Status Not Open Access
Volume 452
Issue 1-2
Start page 412
End page 420
Total pages 9
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Language eng
Abstract The main purpose of this study was to investigate the potential of self-nano-emulsifying drug delivery system (SNEDDS) in improving the bioavailability of docetaxel (DCT) and its chemotherapeutic effect. The DCT-loaded SNEDDS was prepared by employing rational blends of capryol 90, labrasol, and transcutol HP using ternary phase diagram. The liquid nano-emulsion was spray-dried into solid SNEDDS (D-SNEDDS) using an inert porous carrier, colloidal silica. The optimized formulation was characterized in terms of physico-chemical and pharmacokinetic parameters. Furthermore, anti-tumor efficacy of D-SNEDDS was compared with commercial marketed product, Taxotere®. The various compositions of SNEDDS were screened and found optimal at a volume ratio of 10/75/15 for capryol 90, labrasol, and transcutol HP, respectively. We observed a high oral bioavailability of 17% DCT for D-SNEDDS than compared to only 2.6% for pure DCT solution. Notably, D-SNEDDS exhibited an augmented anti-tumor efficacy with a reduced toxicity profile when compared with intravenously administered Taxotere®, the commercialized formulation of DCT. Taken together, D-SNEDDS could be a potential candidate for an oral dosage form of DCT with enhanced antitumor activity and reduced toxicity.
Keyword Anti-tumor efficacy
Bioavailability
Docetaxel
Self-nanoemulsifying drug delivery systems
Toxicity
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 28 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 34 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 04 Jun 2016, 12:27:25 EST by Nirmal Marasini on behalf of School of Chemistry & Molecular Biosciences